RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma

High-throughput Phenotyping of Lung Cancer Somatic Mutations

(2016) Alice H. Berger et al.   CANCER CELL

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

(2014) Marcin Imielinski et al.   JOURNAL OF CLINICAL INVESTIGATION

Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration

(2014) J. Mooz et al.   Science Signaling

RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation

(2013) Matthew Holderfield et al.   CANCER CELL

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Histopathological atlas and proposed classification for melanocytic lesions inTyr::NRasQ61K; Cdkn2a−/−transgenic mice

(2013) Cécile Campagne et al.   Pigment Cell & Melanoma Research

Activated Mutant NRasQ61K Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism

(2012) Ang Li et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

(2012) I V Fedorenko et al.   ONCOGENE

Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis

(2012) F Kern et al.   ONCOGENE

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers

(2012) A P Rebocho et al.   ONCOGENE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance

(2012) Agathe Valluet et al.   Cell Reports

c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

(2011) Rafael B. Blasco et al.   CANCER CELL

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D

(2011) Florian A. Karreth et al.   Cancer Discovery

A Mouse Model of Melanoma Driven by Oncogenic KRAS

(2010) C. Milagre et al.   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation

(2010) P J Mishra et al.   ONCOGENE

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

(2010) F M Kaplan et al.   ONCOGENE

Raf-1 Addiction in Ras-Induced Skin Carcinogenesis

(2009) Karin Ehrenreiter et al.   CANCER CELL

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

(2009) M. A. Davies et al.   CLINICAL CANCER RESEARCH

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas

(2008) Caroline Kannengiesser et al.   Molecular Oncology